Veradigm
Veradigm sells electronic health record software to doctors and hospitals.
On the record
Checkpoint: FY2025 10-K filing and attempted national exchange relisting
The call
Veradigm survives on locked-in EHR customers while revenue, cash, and headcount all shrink, pointing toward a likely private-equity buyout.
Veradigm makes electronic health record software that hospitals and doctors use to store patient information. It is hard to replace because hospitals have spent years training staff on their system and switching would be expensive and disruptive, but this advantage is weakening as competitors like athenahealth and Epic Systems offer better products. The company's revenue has fallen for three straight years, its cash dropped by half, and workers call the software old-fashioned. The one thing that could save it is if its smaller data business, which sells real patient information to drug makers for research, grows fast enough to become the main reason to own the company instead of the struggling software side.
Why
01
AI pressure: Abridge, Nuance DAX Copilot, and other ambient-AI scribing tools. Ambient AI note-taking is now standard across the industry, so Veradigm's own version no longer sets it apart from free or cheaper tools. Could AI do the core job? Yes, likely.
02
Bigger players: Epic Systems, Oracle Health, athenahealth. Epic and Oracle Health keep winning hospital contracts while PE-backed rivals like NextGen and Greenway undercut on price. Could a giant copy it? Yes, easily.
03
What protects it. Doctors rarely switch EHR systems once trained on one, so Veradigm keeps existing customers even as the product falls behind.
What would change this call
Veradigm files its FY2025 10-K on time and relists on a national exchange. Shows whether reporting and compliance credibility are actually recovering.
Life Sciences/RWE segment revenue grows past 25% YoY in a coming quarterly report. Shows whether the data business can offset core EHR decline.
A take-private or acquisition announcement involving Veradigm. Would confirm the company is being absorbed rather than turning around independently.
Life Sciences/RWE segment revenue grows past 25% YoY in a coming quarterly report. Shows whether the data business can offset core EHR decline.
A take-private or acquisition announcement involving Veradigm. Would confirm the company is being absorbed rather than turning around independently.
Key numbers
- Revenue fell to $589M in 2025 from $626M in 2023
- Cash dropped from $294M to $120M in one year
- Cut 15% of staff, closing Chicago HQ by 2027
Named risks
- Cash fell from $294.3M to about $120M in one year (2025), raising liquidity pressure.
- Core EHR product described as 'archaic' by customers versus better-rated peers.
- Active securities-fraud class action over 2020-2024 revenue misstatements.
- Website-tracking wiretap lawsuit (Doe v. Veradigm) allowed to proceed as of July 2026.
- Poison pill and takeover speculation signal possible loss of independence via take-private deal.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| athenahealth | gaining on | KLAS rated athenahealth 77% satisfied vs Veradigm called 'archaic' by users, 2025-06-23 |
| NextGen Healthcare | gaining on | PE-owned NextGen has more capital for modernization against Veradigm's recovering balance sheet, 2026 |
| Greenway Health | gaining on | PE-owned Greenway competes in same ambulatory EHR mid-market as Veradigm, 2026 |
| Epic Systems | contesting | Epic dominates large hospital-system EHR tier above Veradigm's ambulatory focus |
| Oracle Health | contesting | Oracle Health (formerly Cerner) competes in hospital EHR with voice-AI tools, 2026 |
| eClinicalWorks | gaining on | eClinicalWorks offers Sunoh.ai ambient scribe matching Veradigm's Nov 2025 enhanced scribe |
Questions people ask
- Is Veradigm profitable in 2026?
- Veradigm's FY2025 GAAP revenue was guided at $584-589M, down about 1% from FY2024's $594.4M, per its Feb 17, 2026 business update. Cash fell from $294.3M to about $120M during 2025, showing continued cash burn rather than clear profitability.
- Is Veradigm doing layoffs?
- Yes. Veradigm cut 15% of its workforce in 2025, closed three facilities with two more planned in 2026, and announced it will vacate its Chicago headquarters by mid-2027, according to Healthcare Dive reporting from Feb 19, 2026.
- Could AI replace Veradigm's product?
- Unlikely to fully replace it, but AI is commoditizing part of its offering. Veradigm's Ambient Scribe (launched Nov 2024, enhanced Nov 2025) matches similar tools from athenahealth, Epic, Oracle Health and eClinicalWorks, making scribing table-stakes rather than a differentiator.
- Who owns Veradigm?
- Veradigm is a publicly traded company (OTC: MDRX) after Nasdaq delisted it on Feb 29, 2024 for years of unfiled reports. Ownership is dispersed among public shareholders; its board extended a poison-pill rights plan through Dec 31, 2026 amid takeover speculation.
- Is Veradigm being acquired or taken private?
- No confirmed deal as of mid-2026, but Veradigm's board extended its Stockholder Rights Plan (poison pill) through Dec 31, 2026, filed Feb 2, 2026, a move typically used to deter or manage unsolicited takeover interest.
- Is it safe to take a job at Veradigm?
- Mixed signals: Veradigm cut 15% of staff and is closing its Chicago HQ by mid-2027, while simultaneously doubling its India-based headcount (about 37% of global staff as of April 27, 2026), suggesting US roles carry more risk than offshore ones.
Timeline
- 2026-07-08Judge denies motion to dismiss in Doe v. Veradigm website-tracking wiretap lawsuit
- 2026-06-12Payments issued in $10.5M settlement over Dec 2024 data breach affecting ~2M patients
- 2026-05-26Veradigm files combined FY2023/FY2024 10-K, reports $594.4M 2024 revenue
- 2026-04-27Veradigm doubles India-based headcount, names new India Managing Director
- 2026-04-06Christian Greyenbuhl named CFO; market cap about $714M at $4.40/share
- 2026-02-26SEC closes investigation into Veradigm with no enforcement action
- 2026-02-19Veradigm confirms 15% 2025 workforce cut and planned Chicago HQ exit by mid-2027
- 2026-02-17Veradigm issues FY2025 revenue guidance of $584-589M, down ~1%
- 2026-02-02Board extends Stockholder Rights Plan (poison pill) through Dec 31, 2026
- 2024-02-29Nasdaq delists Veradigm for failing to file reports since Nov 2022
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Veradigm Provides Business and Strategy Update (2026-02-17)
- Veradigm Files 2023 and 2024 Form 10-K (2026-05-26)
- Veradigm (2026-07-22)
- Veradigm reports $589 million revenue for 2025 (2026-02-17)
- Veradigm Number of Employees 2026 (2026-06-29)
- Veradigm cut 15% of its workforce in 2025 (2026-02-19)
- Veradigm Doubles India-Based Employee Footprint (2026-04-27)
- Investor Relations (2024-03-19)
- Veradigm Launches Enhanced Ambient Scribe Capabilities (2025-11-17)
- Veradigm to Acquire ScienceIO (2024-02-26)
- What Real-World Data Reveals About Women's Health
- How 6 ambulatory EHR providers stack up (2025-06-23)